Track Altimmune, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Altimmune, Inc. 0A4C.L · Stock Open Altimmune, Inc. in new tab

6.11 USD
EPS
-2.39
P/B
2.85
ROE
-63.29
Beta
0.11
Loading chart...
Key Metrics
EPS-2.39
Book Value2.15
Price to Book2.85
Debt/Equity1.22
% Insiders0.788%
Growth
Revenue Growth-0.17%

DCF valuation

Model fair value for Altimmune, Inc. (0A4C.L)
Result
Sign in to run the valuation for 0A4C.L.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–

Altimmune, Inc. Logo Altimmune, Inc. Analysis (0A4C.L)

United States Health Care Official Website Stock

Is Altimmune, Inc. a good investment? Altimmune, Inc. (0A4C.L) is currently trading at 6.11 USD.

Investor FAQ

Does Altimmune, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Altimmune, Inc.?

Altimmune, Inc. is classified as a Stock. You can compare it against 4 other assets in the "Related Symbols" list on this page.

Company Profile

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

Exchange Ticker
MEX (Mexico) ALT1.MX
FRA (Germany) 3G0.F
NMS (United States) ALT
LSE (United Kingdom) 0A4C.L
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion